Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Zimmer Biomet Holdings, Inc. stock analysis ZBH overview
Somewhat Bullish +50

Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Unpacking its 6.02% ...

📈 Zimmer Biomet trades at $93.1 with a market cap of $18.01 billion, positioned above key moving averages indicating bullish momentum.

📊 The company reports robust revenue growth of 9.30% and maintains a forward P/E ratio of 10.36.

💰 Investors receive a dividend yield of 1.03% supported by a conservative 24.87% payout ratio.

👍 Analyst consensus is positive with 8 buy ratings and an average price target of $98.70.

🤖 Strategic focus on innovation includes the ROSA Robot and ZBEdge Platform for enhanced surgical outcomes.

📉 Technical indicators show an RSI of 55.68 and a MACD buy signal at 1.32 above the signal line.

🎯 Price targets range from $83.00 to $130.00, reflecting varying analyst views on future growth.

Bullish Signals
  • Zimmer Biomet demonstrates robust revenue growth of 9.30%, indicating successful market expansion in the competitive medical device industry.
  • The stock trades above both its 50-day and 200-day moving averages, suggesting healthy short-term bullish momentum.
  • Analysts provide a consensus average price target of $98.70, implying a potential upside of 6.02% from the current trading price.
  • The company maintains a conservative dividend payout ratio of 24.87%, ensuring financial flexibility while returning value to shareholders.
  • Zimmer Biomet solidifies its market leadership through advanced innovations like the ROSA Robot and ZBEdge Platform, leveraging AI for better surgical outcomes.
Full Analysis
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a U.S.-based medical device company with a market capitalization of $18.01 billion, specializing in orthopedic reconstructive products. The stock is currently trading at $93.1, showing a modest 2.14 point increase or 0.02% change, and sits slightly above its 50-day and 200-day moving averages, indicating short-term bullish momentum. Financial metrics reveal robust revenue growth of 9.30%, while the forward P/E ratio stands at 10.36, suggesting reasonable valuation relative to anticipated earnings. The company offers a dividend yield of 1.03% with a conservative payout ratio of 24.87%, balancing shareholder returns with financial flexibility despite the absence of trailing P/E or PEG data. Analyst consensus remains largely positive, comprising 8 buy ratings and 17 holds against just 1 sell rating. The average price target is set at $98.70, implying a potential upside of 6.02% from current levels, with targets ranging widely between $83.00 and $130.00 reflecting divergent views on growth trajectory. Strategically, Zimmer Biomet leverages integrated digital and robotic technologies like the ROSA Robot and ZBEdge Platform to enhance surgical outcomes through data analytics and AI. These innovations solidify its leadership in medical technology, positioning the company for continued expansion within the competitive healthcare sector.